| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 B.R.A.H.M.S Biotechnology Centre Hennigsdorf/Berlin, D-16761 Hennigsdorf bei Berlin, Germany.
2 Klinik für Nuklearmedizin, Universität Würzburg, D-97080 Würzburg, Germany.
aAddress correspondence to this author at: Research Department, B.R.A.H.M.S AG, Neuendorfstrasse 25, D-16761 Hennigsdorf bei Berlin, Germany. Fax 49-03302-883-451; e-mail n.morgenthaler{at}brahms.de.
Background: After removal of differentiated thyroid carcinoma (DTC), serum thyroglobulin (Tg) can indicate persistent or recurrent disease. We describe two novel two-step assays designed to measure low Tg concentrations.
Methods: We evaluated prototypes of the new IRMA, DYNOtest® Tg-pluS, and the new immunoluminometric assay (ILMA), LUMItest® Tg-pluS. In the first step, a high-salt incubation buffer leads to dissociation of Tg-Tg antibody complexes in serum and is intended to reduce nonspecific interference and interference of potential Tg autoantibodies in the system. We studied recovery of human Tg (from thyroid glands) added to horse serum. We also studied 58 patients with DTC in whom Tg values under thyroid-stimulating hormone (TSH) suppression and TSH stimulation (without thyroxine) were available.
Results: The detection limits were 0.04 µg/L Tg for the IRMA and 0.02 µg/L for the ILMA. Intraassay imprecision (CV) was <10% over the range of the calibration curve in both assays. The day-to-day CV was <20% at 0.2 µg/L for the IRMA and at 0.06 µg/L for the ILMA. No high-dose hook effect was seen with up to 200 000 µg/L added Tg or in dilutions of 12 patient sera with Tg values of 307–38 880 µg/L. Mean recovery of 50 µg Tg/L was 96% in those patients. Among 77 samples with Tg antibody values of 65.2–8150 kilounits/L, recovery by the IRMA was disturbed in 7 cases (9%) and by the ILMA in 9 cases (12%). Tg increased as measured in both assays in 50 of 58 patients after thyroxine withdrawal.
Conclusions: The new assays have improved precision for Tg <1 µg/L, and even low measured Tg concentrations respond physiologically to thyroxine withdrawal. The assays are free of a high-dose hook effect up to a Tg concentration of at least 38 000 µg/L and may further reduce Tg antibody interference.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Hovens, M. P. Stokkel, J. Kievit, E. P. Corssmit, A. M. Pereira, J. A. Romijn, and J. W. A. Smit Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2610 - 2615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Gorges, M Maniecki, W Jentzen, S. n-Y. Sheu, K Mann, A Bockisch, and O E Janssen Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy Eur. J. Endocrinol., July 1, 2005; 153(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, and S. K. G. Grebe Phantoms in the Assay Tube: Heterophile Antibody Interferences in Serum Thyroglobulin Assays J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3069 - 3074. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
